Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Patient Preference Studies During Early Drug Development: Aligning Stakeholders to Ensure Development Plans Meet Patient Needs.

Cook NS, Cave J, Holtorf AP.

Front Med (Lausanne). 2019 Apr 24;6:82. doi: 10.3389/fmed.2019.00082. eCollection 2019.

2.

Patient Needs, Perceptions, and Attitudinal Drivers Associated with Obesity: A Qualitative Online Bulletin Board Study.

Cook NS, Tripathi P, Weiss O, Walda S, George AT, Bushell A.

Adv Ther. 2019 Apr;36(4):842-857. doi: 10.1007/s12325-019-00900-1. Epub 2019 Mar 11.

PMID:
30859499
3.

Patients' perspectives on COPD: findings from a social media listening study.

Cook NS, Kostikas K, Gruenberger JB, Shah B, Pathak P, Kaur VP, Mudumby A, Sharma R, Gutzwiller FS.

ERJ Open Res. 2019 Feb 11;5(1). pii: 00128-2018. doi: 10.1183/23120541.00128-2018. eCollection 2019 Feb.

4.

Understanding Patient Preferences and Unmet Needs in Non-alcoholic Steatohepatitis (NASH): Insights from a Qualitative Online Bulletin Board Study.

Cook NS, Nagar SH, Jain A, Balp MM, Mayländer M, Weiss O, Chatterjee S.

Adv Ther. 2019 Feb;36(2):478-491. doi: 10.1007/s12325-018-0856-0. Epub 2018 Dec 13.

PMID:
30547371
5.

Chronic graft loss: dealing with the vascular alterations in solid organ transplantation.

Cook NS, Zerwes HG, Rudin M, Beckmann N, Schuurman HJ.

Transplant Proc. 1998 Aug;30(5):2413-8. Review. No abstract available.

PMID:
9723522
6.

Preclinical models of chronic rejection: promises and pitfalls.

Schuurman HJ, Weckbecker G, Bruns C, Beckman N, Rudin M, Cook NS.

Transplant Proc. 1997 Sep;29(6):2624-5. No abstract available.

PMID:
9290767
7.

Thrombin inhibition in an ex vivo model of porcine heart xenograft hyperacute rejection.

Robson SC, Young VK, Cook NS, Metternich R, Kasper-Konig W, Lesnikoski BA, Pierson RN 3rd, Hancock WW, Candinas D, White DJ, Bach FH.

Transplantation. 1996 Mar 27;61(6):862-8.

PMID:
8623150
8.

Pharmacological inhibition of restenosis: learning from experience.

Shaw LA, Rudin M, Cook NS.

Trends Pharmacol Sci. 1995 Dec;16(12):401-4. Review. No abstract available.

PMID:
8578610
9.

Decreased lumen size after balloon injury despite inhibition of neointimal thickening and antivasospastic treatment.

Cook NS, Zerwes HG, Pally C, Rudin M, Hof RP.

Cardiovasc Res. 1994 Feb;28(2):215-20.

PMID:
8143303
11.

Structure and function of thrombin receptors.

Tapparelli C, Metternich R, Cook NS.

Trends Pharmacol Sci. 1993 Dec;14(12):426-8. Review. No abstract available.

PMID:
8122316
13.

Synthetic low-molecular weight thrombin inhibitors: molecular design and pharmacological profile.

Tapparelli C, Metternich R, Ehrhardt C, Cook NS.

Trends Pharmacol Sci. 1993 Oct;14(10):366-76. Review.

PMID:
8296393
14.
15.

Therapeutic potential of potassium channel openers in peripheral vascular disease and asthma.

Cook NS, Chapman ID.

Cardiovasc Drugs Ther. 1993 Aug;7 Suppl 3:555-63.

PMID:
8251425
16.

Analysis of fine-needle aspirates for HPV by PCR may be useful in diagnosis of metastatic gynecologic malignancies.

Macri CI, Cook NS, Walker JL, Berman ML, Patton TJ Jr, Wilczynski SP.

Gynecol Oncol. 1992 Sep;46(3):372-6.

PMID:
1326475
17.

New developments in cardiovascular magnetic resonance imaging and spectroscopy.

Rudin M, Zierhut W, Sauter A, Cook NS.

Trends Pharmacol Sci. 1991 Nov;12(11):416-21. Review.

PMID:
1796495
18.

Angiotensin II can regulate gene expression by the AP-1 binding sequence via a protein kinase C-dependent pathway.

Takeuchi K, Nakamura N, Cook NS, Pratt RE, Dzau VJ.

Biochem Biophys Res Commun. 1990 Nov 15;172(3):1189-94.

PMID:
2244902
19.

Fibrinogen as a major risk factor in cardiovascular disease.

Cook NS, Ubben D.

Trends Pharmacol Sci. 1990 Nov;11(11):444-51. Review.

PMID:
2267668
20.

Moving together: K+ channel openers and ATP-sensitive K+ channels.

Quast U, Cook NS.

Trends Pharmacol Sci. 1989 Nov;10(11):431-5. Review. No abstract available.

PMID:
2692253
21.
22.

Effect of some potassium channel blockers on contractile responses of the rabbit aorta.

Cook NS.

J Cardiovasc Pharmacol. 1989 Feb;13(2):299-306.

PMID:
2468961
24.
25.

Cardiovascular effects of apamin and BRL 34915 in rats and rabbits.

Cook NS, Hof RP.

Br J Pharmacol. 1988 Jan;93(1):121-31.

26.

The pharmacology of potassium channels and their therapeutic potential.

Cook NS.

Trends Pharmacol Sci. 1988 Jan;9(1):21-8. Review. No abstract available.

PMID:
3072727
27.

Pertussis toxin treatment does not inhibit the effects of the potassium channel opener BRL 34915 on rat isolated vascular and cardiac tissues.

Quast U, Scholtysik G, Weir SW, Cook NS.

Naunyn Schmiedebergs Arch Pharmacol. 1988 Jan;337(1):98-104.

PMID:
2452990
28.

Similarities in the mechanism of action of two new vasodilator drugs: pinacidil and BRL 34915.

Cook NS, Quast U, Hof RP, Baumlin Y, Pally C.

J Cardiovasc Pharmacol. 1988 Jan;11(1):90-9.

PMID:
2450263
29.
30.
31.
32.
34.

Calcium-activated potassium channels in liver cells.

Jenkinson DH, Haylett DG, Cook NS.

Cell Calcium. 1983 Dec;4(5-6):429-37. Review.

PMID:
6323005
35.

High affinity binding of [125I]monoiodoapamin to isolated guinea-pig hepatocytes.

Cook NS, Haylett DG, Strong PN.

FEBS Lett. 1983 Feb 21;152(2):265-9.

Supplemental Content

Support Center